Company profile: Valo Therapeutics
1.1 - Company Overview
Company description
- Provider of immuno-oncology platforms developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. Offerings include PeptiCRAd (oncolytic adenoviruses plus tumor-specific peptides), PeptiENV (oncolytic enveloped viruses with peptides), PeptiVAX (peptide-based cancer vaccines), PeptiBAC (bacteria delivering tumor peptides), and PeptiCHIP (microchip-based tumor neoantigen identification).
Products and services
- PeptiCRAd: A custom-engineered platform combining oncolytic adenoviruses with tumor-specific peptides to direct immune activity, creating therapeutic vaccines that target and kill cancer cells
- PeptiENV: A modular platform using oncolytic enveloped viruses combined with tumor-specific peptides to create personalized cancer treatments by eliciting targeted anti-tumor immune responses
- PeptiCHIP: A microchip-based system enabling rapid, accurate identification of tumor neoantigens from small tumor biopsies to architect personalized cancer immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Valo Therapeutics
Corvus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corvus Pharmaceuticals company profile →
Alentis Therapeutics
HQ: Switzerland
Website
- Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alentis Therapeutics company profile →
Replimune
HQ: United States
Website
- Description: Provider of next-generation oncolytic immunotherapies for cancer, developing proprietary products that enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. Products include RP1 (HSV-1 strain with immune-activating transgenes), RP2 (anti-CTLA-4 antibody targeting immunologically silent tumors to enhance tumor killing and immune response), and RP3 (CD40L and 4-1BBL ligands).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Replimune company profile →
BlossomHill Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on oncology and autoimmune disorders, including FDA-approved repotrectinib (AUGTYRO) for ROS1+ NSCLC, crizotinib (XALKORI) and lorlatinib (LORBRENA), and pipeline candidates elzovantinib (TPX-0022) and TPX-0046, both in Phase 1 studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlossomHill Therapeutics company profile →
Oncoinvent
HQ: Norway
Website
- Description: Provider of radiopharmaceutical cancer treatments, including Radspherin for metastatic cancers in body cavities using alpha-emitting microparticles. Operates a GMP-standard facility for radiopharmaceutical production supporting large multi-center clinical studies. Develops a pipeline of radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products, with proprietary antibodies as targeting modules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoinvent company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Valo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Valo Therapeutics
2.2 - Growth funds investing in similar companies to Valo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Valo Therapeutics
4.2 - Public trading comparable groups for Valo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →